IS3030B - Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu - Google Patents

Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu

Info

Publication number
IS3030B
IS3030B IS8077A IS8077A IS3030B IS 3030 B IS3030 B IS 3030B IS 8077 A IS8077 A IS 8077A IS 8077 A IS8077 A IS 8077A IS 3030 B IS3030 B IS 3030B
Authority
IS
Iceland
Prior art keywords
macrocylic
antiproliferative agents
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
IS8077A
Other languages
English (en)
Other versions
IS8077A (is
Inventor
Eddy Freyne
Timothy Perera
Peter Buijnsters
Marc Willems
Gaston Marvella
Werner EMBRECHTS
Peter Holte
Frederk Rombouts
Carsten Schulz-Fademrecht
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33493782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS3030(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IS8077A publication Critical patent/IS8077A/is
Publication of IS3030B publication Critical patent/IS3030B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS8077A 2003-05-27 2005-10-14 Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu IS3030B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP0305723 2003-05-27
EP0310266 2003-09-15
EP0351061 2003-12-18
PCT/EP2004/005621 WO2004105765A1 (en) 2003-05-27 2004-05-25 Macrocyclic quinazoline derivatives as antiproliferative agents

Publications (2)

Publication Number Publication Date
IS8077A IS8077A (is) 2005-10-14
IS3030B true IS3030B (is) 2021-06-15

Family

ID=33493782

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8077A IS3030B (is) 2003-05-27 2005-10-14 Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu

Country Status (31)

Country Link
US (4) US7648975B2 (is)
EP (2) EP2305687A1 (is)
JP (1) JP4887151B2 (is)
KR (1) KR101143878B1 (is)
CN (1) CN102718775B (is)
AR (2) AR045687A1 (is)
AT (1) ATE544454T1 (is)
AU (1) AU2004243487B2 (is)
BR (1) BRPI0410714B8 (is)
CA (1) CA2525214C (is)
CL (1) CL2004001267A1 (is)
CO (1) CO5640038A2 (is)
CY (1) CY1113002T1 (is)
DK (1) DK1633365T3 (is)
EA (1) EA009064B1 (is)
ES (1) ES2381976T3 (is)
HR (1) HRP20120351T1 (is)
IL (3) IL172154A0 (is)
IS (1) IS3030B (is)
JO (1) JO2785B1 (is)
MX (1) MXPA05012762A (is)
MY (1) MY148633A (is)
NO (1) NO334209B1 (is)
NZ (1) NZ544154A (is)
PA (1) PA8603801A1 (is)
PL (1) PL1633365T3 (is)
PT (1) PT1633365E (is)
SI (1) SI1633365T1 (is)
TW (3) TWI468397B (is)
UA (1) UA84010C2 (is)
WO (1) WO2004105765A1 (is)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
AU2004298448B2 (en) * 2003-12-18 2010-09-09 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
EA200601176A1 (ru) 2003-12-18 2006-10-27 Янссен Фармацевтика Н.В. 3-цианохинолиновые производные с антипролиферативной активностью
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) * 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
AU2006216266C1 (en) 2005-02-23 2010-08-26 Shionogi & Co., Ltd. Quinazoline derivative having tyrosine kinase inhibitory activity
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
UA92608C2 (en) * 2005-06-30 2010-11-25 Янссен Фармацевтика Н.В. Cyclic anilino - pyridinotriazines as gsk-3 inhibitors
CA2654583C (en) * 2006-07-13 2015-11-24 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
JP2009242240A (ja) * 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
AU2007296745B2 (en) * 2006-09-11 2011-12-01 Curis, Inc. Quinazoline based EGFR inhibitors
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2662617C (en) 2006-09-11 2014-11-18 Changgeng Qian Quinazoline based egfr inhibitors containing a zinc binding moiety
CA2664148A1 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv Vegfr3 inhibitors
EP2077843A1 (en) * 2006-10-27 2009-07-15 Janssen Pharmaceutica N.V. Use of a mt kinase inhibitor for treating or preventing brain cancer
EP2407783A1 (en) 2006-10-27 2012-01-18 Janssen Pharmaceutica, N.V. A method for pharmacologically profiling compounds
CA2664165A1 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv Use of mtki 1 for treating or preventing bone cancer
EP2123627B1 (en) * 2007-01-19 2013-11-20 Ube Industries, Ltd. Process for producing aromatic amine having aralkyloxy or heteroaralkyloxy group
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI406853B (zh) * 2010-04-07 2013-09-01 Dev Center Biotechnology Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
WO2013126015A1 (en) 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
US9499532B2 (en) * 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
MA39823A (fr) * 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10716869B2 (en) 2016-02-29 2020-07-21 Oncodesign Sa Radiolabeled macrocyclic EGFR inhibitor
UA125025C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Способи лікування дитячих ракових захворювань
UA125026C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
MX392604B (es) 2016-05-18 2025-03-24 Array Biopharma Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo.
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3720438B1 (en) * 2017-12-07 2023-08-30 Amplyx Pharmaceuticals, Inc. Heterocycle substituted pyridine derivative antifungal agents
JP2021530445A (ja) 2018-06-25 2021-11-11 アンプリックス ファーマシューティカルズ，インク． 複素環およびアミノ基によって置換されたピリジン誘導体
CA3168814A1 (en) * 2020-01-31 2021-08-05 Oncodesign S.A. Macrocyclic rip2-kinase inhibitors
WO2021216440A1 (en) * 2020-04-20 2021-10-28 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
JP2025500917A (ja) 2021-12-16 2025-01-15 キネート バイオファーマ インク． Ｍｅｔキナーゼの阻害剤
WO2024017258A1 (zh) * 2022-07-19 2024-01-25 百极弘烨(南通)医药科技有限公司 Egfr小分子抑制剂、含其的药物组合物及其用途
WO2026008023A1 (zh) * 2024-07-04 2026-01-08 正大天晴药业集团股份有限公司 哒嗪胺类化合物及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558251A (is) * 1956-06-11
DE2423536A1 (de) * 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US4160836A (en) 1976-05-17 1979-07-10 Janssen Pharmaceutica N.V. Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN1158266C (zh) 1998-10-01 2004-07-21 阿斯特拉曾尼卡有限公司 化合物
FR2809400B1 (fr) * 2000-05-25 2004-04-09 Inst Francais Du Petrole Materiaux comportant des groupements organiques contenant du soufre et du phosphore lie par l'intermediaire d'atomes d'oxygenes a un oxyde mineral
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف

Also Published As

Publication number Publication date
US9273013B2 (en) 2016-03-01
JP4887151B2 (ja) 2012-02-29
ES2381976T3 (es) 2012-06-04
CA2525214A1 (en) 2004-12-09
UA84010C2 (en) 2008-09-10
HRP20120351T1 (hr) 2012-05-31
US20160207938A1 (en) 2016-07-21
IL172154A0 (en) 2006-04-10
ATE544454T1 (de) 2012-02-15
AU2004243487B2 (en) 2009-12-03
SI1633365T1 (sl) 2012-06-29
EA200501866A1 (ru) 2006-06-30
AU2004243487A1 (en) 2004-12-09
JP2007504276A (ja) 2007-03-01
HK1176350A1 (zh) 2013-07-26
BRPI0410714B1 (pt) 2019-09-24
BRPI0410714B8 (pt) 2021-05-25
EP2305687A1 (en) 2011-04-06
EP1633365A1 (en) 2006-03-15
WO2004105765A1 (en) 2004-12-09
KR20060014415A (ko) 2006-02-15
IL233045A0 (en) 2014-07-31
IL233045B (en) 2018-07-31
MY148633A (en) 2013-05-15
BRPI0410714A (pt) 2006-06-13
PL1633365T3 (pl) 2012-07-31
CY1113002T1 (el) 2016-04-13
US20100105668A1 (en) 2010-04-29
TW200510431A (en) 2005-03-16
CN102718775A (zh) 2012-10-10
CO5640038A2 (es) 2006-05-31
TWI379835B (en) 2012-12-21
TW201245160A (en) 2012-11-16
IL233046A0 (en) 2014-07-31
US20060247237A1 (en) 2006-11-02
PA8603801A1 (es) 2004-12-16
TWI468397B (zh) 2015-01-11
MXPA05012762A (es) 2006-02-13
US20130178624A1 (en) 2013-07-11
NO20056196L (no) 2005-12-28
DK1633365T3 (da) 2012-05-14
KR101143878B1 (ko) 2012-05-24
PT1633365E (pt) 2012-05-07
AR045687A1 (es) 2005-11-09
CA2525214C (en) 2012-11-27
TW201245111A (en) 2012-11-16
EP1633365B1 (en) 2012-02-08
US7648975B2 (en) 2010-01-19
CN102718775B (zh) 2016-02-17
NZ544154A (en) 2009-01-31
TWI468372B (zh) 2015-01-11
JO2785B1 (en) 2014-03-15
CL2004001267A1 (es) 2005-04-22
NO334209B1 (no) 2014-01-13
IS8077A (is) 2005-10-14
AR092137A2 (es) 2015-03-25
US8394786B2 (en) 2013-03-12
EA009064B1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
IL233046A0 (en) Quinazoline macrocyclic derivatives as antiproliferative agents
IL174533A0 (en) Quinazoline derivatives as antiproliferative agents
IL174534A0 (en) Quinazoline derivatives
GB0321648D0 (en) Quinazoline derivatives
IL174284A0 (en) Quinazoline derivatives
GB0215823D0 (en) Quinazoline derivatives
PT1847539E (pt) Derivados de quinazolina
PL378245A1 (pl) Pochodne pirolopirydazyny
GB0317665D0 (en) Qinazoline derivatives
PL1682493T3 (pl) Pochodne amidoacetonitrylu
PL1606277T3 (pl) Pochodne imidazol-4-iloetynylo-pirydyny
IL174390A0 (en) Quinazoline derivatives
GB0326459D0 (en) Quinazoline derivatives
GB0330002D0 (en) Quinazoline derivatives
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
PL1706373T3 (pl) Pochodne amidoacetonitrylu
ZA200603039B (en) Quinazoline derivatives
PL374817A1 (en) Quinazoline derivatives
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0321620D0 (en) Quinazoline derivatives
HK1091203A (en) Quinazoline derivatives as antiproliferative agents
GB0322535D0 (en) Quinazoline derivatives
GB0317664D0 (en) Quinazoline derivatives
GB0322536D0 (en) Quinazoline derivatives
GB0322458D0 (en) Quinazoline derivatives